Immupharma Share Discussion Threads

[wigwammer] 26/6/2019 14:04

To repeat my previous points. There is no control arm here so what could the results show that would be impactful?1) Higher number of patients cured than would be likely by chance (ie objectively no anti dsDNA) - this was a tendency seen in the ph3 2) Heightened efficacy in patients with positive anti dsDNA relative to those without - again the ph3 results suggested a tendency toward this. Bottom line - even without a control, these results are of great interest to all stakeholders. Perhaps the info will be positive, perhaps not, but certainly of great interest.

[miavoce] 26/6/2019 13:51

Theoretically this subscription / sharing model could be a very astute way to raise funds if IMM are expecting good results from the extension trial (whether IMM have any knowledge of the results I don't know but I guess it is feasible that they do).If the results are good and the share price rises then IMM may get considerably more than 2.66m without having to issue additional shares. This is better than simply issuing the shares now to raise a fixed 2.66m.Of course, if the extension results lead to a fall in the share price then IMM get less than 2.66m, so a standard placing to raise 2.66m would have been a better option.Lasted themselves may also be expecting good results to the extension study otherwise why enter into an agreement that they do notvrxpect to make a decent return onIntriguining to see how this plays out over the next few days.

[ewanwhose] 26/6/2019 13:27

Hope Lanstead have deep pockets!

[kirk 6] 26/6/2019 13:11

We will find out tomorrow! If good news the upside will be enormous as they will be able to raise more cash at a higher price

[chanlfc] 26/6/2019 11:59

Wow the doomers are trying their best after selling out in a panic, shall we see what happens tomorrow?

[njb67] 26/6/2019 11:42

Given they have had to raise money to cover day to day operating costs, I would not be surprised if the suspension is due to lack of funding.

[borromini1] 26/6/2019 11:17

Unstated reason for Managed Access Programme being suspended?

[nobbygnome] 26/6/2019 11:13

STX is a better bet. Four weeks to FDA approval for Ferracru...and it won’t be another Lupuzor as it is already approved in Europe.

[ken chung] 26/6/2019 10:02

More dilution to pay the management salaries of this failed company.

Incredible you don't even need to be running a successful business these days to list on AIM and keep it afloat with regular dilution.

The underlying busines for companies on AIM has almost become irrelevant.

The new AIM business model - No need to even have revenues, just dilute, dilute dilute - the dilution is the revenues.

Just register a company name, list it, then dilute to keep the management on six or seven figure salaries and enjoying luxury lifestyles, and the NOMAD's on their huge fees.

Lemmings and mushrooms only now.

[nobbygnome] 26/6/2019 09:11

The management just continue to shaft the shareholders here.....and don't even give you a chance to take place in the fund raisings! It's just one dilution after another. Truly shocking....

This is a classic Aim story.

[borromini1] 26/6/2019 09:05

Ewan - Lanstead will always be paying at a big discount from the then current share price, at a lower price as calculated by the formula stated in the agreement.

[ewanwhose] 26/6/2019 08:56

If the price goes to 9p, Lanstead will be paying less than 7p.

[njb67] 26/6/2019 08:56

borromini

yes, you are right. the amount is variable, it could be more or less than £100k per month depending on the share price The headline is a projected £2.66m over 24 months, so circa £100k per month.

It would be less though if the share price falls.

[borromini1] 26/6/2019 08:50

njb - you are incorrect Lanstead have not undertaken to pay a fixed £100k per month, the amount to be paid is variable, if the share price doubles the payment roughly doubles.

This agreement seems to be a massive dilution for existing shareholders to fix the loss of capital from an unnecessary investment in Incanthera.

[marwalker] 26/6/2019 08:43

Could IMM develop into a ' shell ' co.?

How this works is when a co. runs out of cash and other options , shareholders forfeit their shares for a tiny sum . ( this is presented as better something than nothing )

After suspension the co . is relaunched with a new name and business.

The rationale for this would be a nice profit for Lansted as up to £2m. is much cheaper than launching a new co. on the Stock Exchange.

[njb67] 26/6/2019 08:41

borromini

I think this is a loan of last resort. Lanstead are giving them circa £100k per month on the hope that IMM can do something with Lupuzor or the other platforms.

Not sure how many shares Lanstead held before this transaction - I have not been close to IMM for a while now - it could simply be that they are providing some extra cash to try and protect their pre-existing holding.

[borromini1] 26/6/2019 08:37

As Lanstead will now own more than 19% of the company they will be reporting any sale or further purchase of shares. There is no mention in the RNS of any restriction on Lanstead selling shares during the agreement period.

So this is effectively a contract to buy 1.1 million shares per month at the going rate minus discount for the next two years. It could bring in substantially more than the initial £2.66m agreement price but only if substantial good news occurs.

[njb67] 26/6/2019 08:15

So in return for giving away 20% of the company, Lanstead will give IMM circa £100k per month over next two years to enable IMM to sell assets that they have failed to sell for the last year or two and progress regulatory/commercial deals that they have also failed to conclude (and it is a sellers market) over the same time period.

If they have to give away 20% of the company for £2m, how much will they need to give away to raise the £50-100m to complete the phase 2 and 3 trials?

IMM is going to limp along for another couple of years until they run out of money again.

Are the Board really acting in shareholders interests?

EDIT: Would also add that it is noteworthy that Lansted are not prepared to give IMM £2m up front but instead £100k per month pocket money. That is how much they trust IMM.

[nobbygnome] 26/6/2019 08:13

>> kirk

Do you really think they would be raising money at such a lowly level if they knew good news was imminent? You are a fantasist. This is just the next stage on the road to nowhere.....but Tim keeps trousering his monthly cash, which is all that matters!

[buywell2] 26/6/2019 07:57

more cash required

buywell2 - 01 Apr 2019 - 08:26:26 - 34013 of 34247 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM

Strike 1 .... Strike 2 .....


buywell2 - 24 Feb 2019 - 19:00:31 - 33977 of 34013 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM

what is a placebo ? read this


buywell3 - 27 Apr 2018 - 10:19:34 - 29505 of 33977 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM
Phase 3 trials are very pricey

To sign up a meaningful number of human guinea pigs to be injected with a trial drug compound ... with unknown toxicology outcomes ... you could be looking at several millions of pounds.

Where is the money coming from after the recent Phase 3 results came out poor at best ie no proven efficay ie the compound didn't do anything measurable that was different to a placebo ie a fake drug/pill that some human guinea pigs have to take at phase 3 in order to see if those taking the real deal drug being tested derive any benefit from taking it ie it has efficacy.

efficacy is the whole reason for a phase 3 clinical trial to see if the drug being tested works

Put me down for one of those please nurse

[kirk 6] 26/6/2019 07:54

This could be a sign of good news tomorrow surely why risk 2m if bad results tomorrow? As bobby says it's make or break tomorrow now so 10p base to me points to good results tomorrow.... in which case it's make!